Lasofoxifene - Sermonix Pharmaceuticals

Drug Profile

Lasofoxifene - Sermonix Pharmaceuticals

Alternative Names: CP-336156; CP-336156-CB; Fablyn; Lasofoxifene tartrate; Oporia

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ligand Pharmaceuticals; Pfizer
  • Developer Pfizer; Sermonix Pharmaceuticals
  • Class Antineoplastics; Osteoporosis therapies; Pyrrolidines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Postmenopausal osteoporosis
  • Preregistration Atrophic vaginitis
  • Phase III Breast cancer
  • Phase II Female sexual dysfunction
  • Research Ovarian cancer
  • No development reported Hypogonadism

Most Recent Events

  • 14 Nov 2017 Sermonix Pharmaceuticals plans a phase II trial for Breast cancer (Late-stage disease, Metastatic disease) in Europe and USA (PO) in the fourth quarter of 2018
  • 31 Oct 2017 Sermonix Pharmaceuticals files for patent protection for lasofoxifene for endocrine-resistant Breast cancer world-wide before October 2017
  • 03 Mar 2017 No development reported - Phase-I for Hypogonadism (In volunteers) in USA (PO) (Sermonix Pharmaceuticals pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top